Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,409 across all filing types
Latest filing 2026-04-27 Transaction in Own Shar…
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 90% confidence The document is a formal declaration by Sanofi of transactions on its own shares (“Déclaration des transactions sur actions propres”) over a specified period, including detailed trade data. This fits the definition for a Transaction in Own Shares report. Hence, it should be classified as POS.
2026-04-27 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 95% confidence The document text primarily contains detailed tabular data about share repurchases by Sanofi, including transaction dates, quantities, prices, and market information. The text explicitly mentions "share repurchases" and provides aggregated daily presentations of these transactions. There is no indication of financial statements, management discussion, earnings highlights, or regulatory certifications. The content is focused on the company's transactions involving its own shares, which aligns with the definition of "Transaction in Own Shares" (POS). The document length is substantial (15,000 characters), indicating it is not a brief announcement but a detailed report of share transactions. Therefore, the most appropriate classification is POS (Transaction in Own Shares).
2026-04-27 English
Communiqué de presse : Sanofi place 2,3 milliard d’euros d’emprunts obligataires
Capital/Financing Update Classification · 92% confidence The document is a press release announcing the successful placement of €2.3 billion of bonds in three tranches under Sanofi’s Euro Medium Term Note program. It details the terms, use of proceeds, and bookrunners — clearly a financing activity update rather than an annual or interim report, dividend notice, or regulatory filing. This fits the Capital/Financing Update category.
2026-04-24 French
Press Release: Sanofi successfully prices 2.3 billion of bond issue
Capital/Financing Update Classification · 90% confidence The document is a press release announcing the pricing and issuance of €2.3 billion in new bond notes across three maturities under Sanofi’s Euro Medium Term Note programme. It details the financing transaction structure, lead managers, use of proceeds, and offering terms. This clearly falls under a Capital/Financing Update announcement rather than an interim report, earnings release, or regulatory filing. Therefore, it should be classified as CAP (Capital/Financing Update).
2026-04-24 English
Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
Regulatory Filings Classification · 87% confidence The document is a corporate press release announcing a positive CHMP opinion for Sanofi’s drug, including forward‐looking statements and media/investor contacts. It does not present financial results, request votes, or constitute an official regulatory or financial report itself. It’s a general announcement that does not fit other specific categories, making it a fallback Regulatory Filing (RNS).
2026-04-24 English
Communiqué de presse : Cenrifki de Sanofi (tolebrutinib) recommandé par le Comité des médicaments à usage humain (CMUH) pour être approuvé par l’UE pour le traitement de la sclérose en plaques seconda
Regulatory Filings Classification · 85% confidence The document is a corporate press release (communiqué de presse) announcing the EU CHMP’s positive recommendation for Sanofi’s drug Cenrifki (tolebrutinib). It contains clinical study details and forward-looking statements, but no financial results, no shareholder or board matters, no dividend/share actions, nor any structured financial report. This falls outside all specific financial filing categories and thus defaults to the general Regulatory Filings category (RNS).
2026-04-24 French

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.